Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of enzalutamide on castration resistant prostate cancer

Next Previous
Trial Profile

Clinical study of enzalutamide on castration resistant prostate cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 May 2023 Results investigating the relationship between the serum testosterone (T) level before ENZ treatment and QoL changes in CRPC patients, published in the Prostate
    • 19 Feb 2022 Results investigating the relationship between serum testosterone (T) levels before ENZ and QOL changes in CRPC patients, presented at the 2022 Genitourinary Cancers Symposium
    • 13 Sep 2021 Results of an analysis assessing the the relationship between the efficacy of Enzalutamide on castration resistant prostate cancer and serum androgen concentrations before administration presented at the 116th Annual Meeting of the American Urological Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top